IP Library Granted Patent US 9,347,946
Granted Patent B2
US 9,347,946 · App. 13/241,083 · Granted May 24, 2016

Methods and reagents for signal amplification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,347,946
App. No.
13/241,083
Granted
May 24, 2016
Kind
B2
Abstract

The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays.

Claims (40)

1. A detectable reagent comprising:

a binding moiety conjugated to a dextran component, wherein the dextran component has a total of about 4 to about 8 dextrans per binding moiety and the binding moiety is not a dextran or a target entity in a sample, and wherein a detectable entity is conjugated to the dextran component.

2. The detectable reagent of claim 1 , wherein each dextran is from about 30 kDa to about 100 kDa molecular weight.

3. The detectable reagent of claim 1 , wherein each dextran is about 70 kDa molecular weight.

4. The detectable reagent of claim 1 , wherein each dextran has substantially the same molecular weight.

5. The detectable reagent of claim 1 , wherein at least one dextran has a molecular weight different from another dextran.

6. The detectable reagent of claim 1 , wherein the detectable entity is a fluorophore.

7. The detectable reagent of claim 6 , wherein the fluorophore is selected from a fluorophore with green fluorescence, orange fluorescence, red fluorescence, and far red fluorescence.

8. The detectable reagent of claim 6 , wherein the fluorophore is selected from a fluorophore with excitation and emission spectra in the range of about 350 nm to 775 nm.

9. The detectable reagent of claim 8 , wherein the fluorophore is selected from a fluorophore with excitation and emission spectra of about 346 nm/446 nm, about 494 nm/519 nm, about 554 nm/570 nm, about 555 nm/572 nm, about 590 nm/617 nm, about 651 nm/672 nm, about 679 nm/702 nm and about 749 nm/775 nm.

10. The detectable reagent of claim 1 , wherein the binding moiety is selected from the group consisting of avidin, streptavidin, biotin, digoxigenin, immunoreagent, oligonucleotide, peptide, protein, nucleic acid, peptide nucleic acid, protein A, protein G, a derivative thereof, and a ligand-binding portion thereof.

11. A method of making a detectable reagent comprising:

providing a dextran component comprising a plurality of inter-connected dextran;

conjugating the dextran component with a binding moiety to form a dextran-binding moiety complex, wherein the binding moiety is not a dextran or a target entity in a sample, and wherein the dextran-binding moiety complex has a total of about 4 to about 8 dextrans per binding moiety; and

attaching a detectable entity to the dextran-binding moiety complex.

12. A method of making a detectable reagent comprising:

conjugating a binding moiety to a dextran to form a core dextran-binding moiety, wherein the binding moiety is not a dextran or a target entity in a sample;

reacting the core dextran-binding moiety with one or more dextrans to form a dextran-binding moiety complex which contains a total of about 4 to about 8 dextrans per binding moiety; and

attaching a detectable entity to the dextran-binding moiety complex.

13. The method of claim 12 , wherein the binding moiety is avidin or strepavidin.

14. A method for detecting or quantifying a target molecule comprising:

contacting the detectable reagent of claim 1 with a sample suspected of containing a target molecule, wherein the binding moiety is capable of binding to the target molecule; and

detecting a signal of the detectable entity thereby detecting or quantifying the target molecule.

15. The detectable reagent of claim 1 , wherein the total molecular weight of dextrans is at least 500 kDa.

16. The detectable reagent of claim 1 , wherein the dextrans within the dextran component are inter-connected and configured in a layered configuration or branched configuration.

17. The detectable reagent of claim 1 , wherein each dextran is from 30 kDa to 100 kDa molecular weight.

18. The detectable reagent of claim 1 , wherein each dextran is from about 50 kDa to about 70 kDa molecular weight.

19. The detectable reagent of claim 1 , wherein the detectable reagent contains a total of about 6 dextrans per binding moiety.

20. The detectable reagent of claim 1 , wherein the detectable reagent contains a total of 6 dextrans per binding moiety.

21. The detectable reagent of claim 1 , wherein the detectable reagent provides an enhanced, increased or amplified detection when compared to a detection achieved from a binding moiety conjugated to a detectable entity in the absence of dextrans or a binding moiety conjugated to a single dextran containing a detectable entity.

22. The detectable reagent of claim 21 , wherein the enhanced, increased or amplified detection is at least about 2 fold more signal compared to detection achieved from a binding moiety conjugated to a detectable entity in the absence of dextrans or a binding moiety conjugated to a single dextran containing a detectable entity.

23. A method of making a detectable reagent of claim 1 comprising:

derivatizing a dextran-amine to generate maleimide functional groups;

derivatizing a binding moiety to generate thiol functional groups, wherein the binding moiety is not a dextran or a target entity in a sample;

reacting the derivatized binding moiety with a molar ratio of one or more derivatized dextran-amine to form a dextran-binding moiety;

derivatizing the dextran-binding moiety to generate one or more thiol groups per dextran;

reacting the derivatized dextran-binding moiety with a molar ratio of one or more derivatized dextran-amine to form an inter-connected dextran-binding moiety complex, wherein the dextran-binding moiety complex has a total of about 4 to about 8 dextrans per binding moiety; and

reacting the inter-connected dextran-binding moiety complex with a molar ratio of one or more detectable entities to form a detectable reagent.

24. The detectable reagent of claim 1 , wherein the binding moiety is avidin or streptavidin.

25. The detectable reagent of claim 1 , wherein the detectable reagent has a total of 4 to 8 dextrans per binding moiety.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2024
From: BIOCEPT, INC.
To: PLUS THERAPEUTICS, INC.
Reel/Frame 067409/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2011
From: MIKOLAJCZYK, STEPHEN D.; MILLAR, LISA S.
To: BIOCEPT, INC.
Reel/Frame 027342/0925 →